ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
Beacon Pharmaceuticals PLC
Generic: Darbepoetin alfa
Safety Advices
বাংলা
English
CONSULT YOUR DOCTOR
It is not known whether it is safe to consume alcohol with Darbesis 25. Please consult your doctor.
CONSULT YOUR DOCTOR
Darbesis 25 may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
SAFE IF PRESCRIBED
Darbesis 25 is probably safe to use during breastfeeding. Limited human data suggests that the drug does not represent any significant risk to the baby.
SAFE
Darbesis 25 does not usually affect your ability to drive.
SAFE IF PRESCRIBED
Darbesis 25 is safe to use in patients with kidney disease. No dose adjustment of Darbesis 25 is recommended.
CAUTION
Darbesis 25 should be used with caution in patients with liver disease. Dose adjustment of Darbesis 25 may be needed. Please consult your doctor.
Medicine Overview of Darbesis 25 25mcg/0.42ml Injection
Introduction
Darbesis 25 is used in the treatment of anemia that may have occurred due to chronic kidney disease or chemotherapy. It works by stimulating the bone marrow to produce more red blood cells. Darbesis 25 is a medicine that needs to be used with utmost care because it can lead to serious side effects. It is important that you seek treatment from a doctor who is experienced in providing this medicine therapy. You should follow all the directions of doctor strictly. It is given under the supervision of a healthcare professional. However, you should not take it, if you have...
... Show moreUses of Darbesis 25
- Anemia due to chronic kidney disease
- Anemia due to cancer chemotherapy
Side effects of Darbesis 25
Common
- High blood pressure
- Hypersensitivity
How to use Darbesis 25
Your doctor or nurse will give you this medicine. Kindly do not self administer.
How Darbesis 25 works
Darbesis 25 is an erythropoiesis-stimulating agent (ESA). It works by stimulating the bone marrow (soft tissue inside the bones which produces red blood cells) to produce more red blood cells.
What if you forget to take Darbesis 25?
If you miss a dose of Darbesis 25, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not double the dose.
Quick Tips
- Darbesis 25 helps in the treatment of anemia that may have occurred due to chronic kidney disease or cancer chemotherapy.
- It is given as a single injection under your skin.
- Your doctor may get your blood tests done regularly to monitor the levels of hemoglobin, blood cells and electrolytes such as potassium in your blood.
- Monitor your blood pressure regularly while taking this medication. Inform your doctor if you notice symptoms of very high blood pressure such as severe headache, problems with your eyesight, nausea, vomiting or fits (seizures).
- Stop taking Darbesis 25 and inform your doctor if you develop shortness of breath or skin rash.
Brief Description
Indication
Anaemia of chronic renal failure, Anaemia in chemotherapy patients
Adult Dose
Chronic Kidney Disease-Associated Anemia
CKD not on dialysis
Recommended starting dose: 0.45 mcg/kg IV/SC q4weeks
Consider initiating ESA treatment only when the hemoglobin level is 1 g/dL in 2-week period)
Discontinue if no response after 8 weeks
Child Dose
Chronic Kidney Disease-Associated Anemia
Initiate treatment when the hemoglobin level is <10 g/dL
If the hemoglobin level approaches or exceeds 12 g/dL, reduce or interrupt the dose
Recommended starting dose for pediatric patients (<18 yr) is 0.45 mcg/kg SC or IV qWeek
Patients not receiving dialysis may also be initiated at a dose of 0.75 mcg/kg q2Week
Chemotherapy-related Anemia
Safety and efficacy not established
Renal Dose
Chronic Kidney Disease-Associated Anemia CKD not on dialysis Recommended starting dose: 0.45 mcg/kg IV/SC q4weeks Consider initiating ESA treatment only when the hemoglobin level is <10 g/dL If the hemoglobin level exceeds 10 g/dL, reduce or interrupt ESA dose and use the lowest dose sufficient to reduce the need for red blood cell transfusions CKD on dialysis Initiate ESA treatment when the hemoglobin level is <10 g/dL If the hemoglobin level approaches or exceeds 11 g/dL, reduce or interrupt the dose of ESA Recommended starting dose: 0.45 mcg/kg IV or SC qWeek or 0.75 mcg/kg q2weeks; the IV route is...
... Show moreContraindication
Hypersensitivity, uncontrolled hypertension.
Mode of Action
Darbepoetin alfa is a biosynthetic form of erythropoietin. Recombinant human erythropoietin with sialic acid additions to enhance stability; stimulates erythropoiesis via division & differentation of progenitor cells in bone marrow to induce the release of reticulocytes from the bone marrow into the bloodstream to become erythrocytes.
Precaution
Hypertension; history of seizures; hepatic impairment; sickle cell anaemia; sudden stabing migraine-like pain (warning sign of hypotensive crisis); exclude other causes of anaemia; ischaemic vascular disease; thrombocytosis; epilepsy; malignant disease; increase in heparin dose may be needed; increased risk of thrombosis when used for anaemia before orthopedic surgery; CV disease including recent MI/cerebrovascular accident. Monitor haemoglobin, BP and electrolytes; platelet count for 1st 8 wk.
Lactation: not known if excreted in breast milk, use caution
Side Effect
>10% Cancer patients Fatigue (33%),Diarrhea (22%),Edema (21%),Fever (19%),Dizziness (14%),Arthralgia (13%),Headache (12%),Death (10%) Chronic renal failure patients Infectious disease (24%),Hyper/Hypotension (20%),Spasm (17%),Upper respiratory infection, Headache (15%),Diarrhea, Vomiting (14%),Nausea (11%),Peripheral edema, Dyspnea (10%),Abdominal pain (10%) 1-10% Cancer patients Myalgia (8%),Hypertension (3.7%),Pneumonia (3%),Dyspnea (2%),Vomiting (2%),Pulmonary embolism (1.3%) Chronic renal failure patients Arthralgia, Cough, Fatigue (9%),Limb pain (8%),Dizziness, Fever (7%),Death (6%),Edema (6%),Anemia, DVT, red cell aplasia (5.6%),Cardiac arrest, Cardiac dysrhythmia, Congestive heart failure (5%),Myocardial infarction, CVA(2%) <1% Cancer patients Hypertensive encephalopathy (0.6%),Seizure (0.6%),Chronic renal failure patients,Hypertensive encephalopathy (<1%),Seizure (<1%),Transient ischemic attack (<1% ) Frequency Not Defined Tumor progression,Venous thromboembolism,Immune hypersensitivity reaction (rare ),Injection site...
... Show morePregnancy Category Note
Pregnancy Limited available data on pregnant women are insufficient to determine a drug-associated risk of major birth defects or miscarriage; in animal reproductive and developmental toxicity studies, drug increased early post-implantation loss at doses approximating clinical recommended starting doses; consider benefits and risks for the mother and possible risks to fetus when prescribing to a pregnant woman Lactation There is no information regarding presence of drug in human milk, effects on breastfed child, or on milk production; the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for therapy and any potential adverse effects...
... Show moreInteraction
Antagonism of hypotensive effect and increased risk of hyperkalemia with ACE inhibitors and angiotensin II receptor antagonists. Ethanol.
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
Beacon Pharmaceuticals PLC
Generic: Darbepoetin alfa
Additional Offers
Cashback
৳100
For purchasing above ৳5000+
Cashback
৳80
For purchasing above ৳4000+
Cashback
৳60
For purchasing above ৳3000+
Cashback
৳40
For purchasing above ৳2000+
Cashback
৳20
For purchasing above ৳1000+
Disclaimer
The information provided herein is accurate, updated and complete as per the best practices of the Company. Please note that this information should not be treated as a replacement for physical medical consultation or advice. We do not guarantee the accuracy and the completeness of the information so provided. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company. We do not take any responsibility for the consequences arising out of the aforementioned information and strongly recommend you for a physical consultation in case of any queries or doubts.
